Innovating for cancer patients METHYS Dx develops innovative liquid biopsy tests for non-invasive monitoring of cancer patients. Combining unique proprietary molecular signatures and a disruptive ultrasensitive detection technology, METHYS Dx tests will allow monitoring of tumor evolution, and early detection of relapses, thus improving patient care through better-informed therapeutic decisions. ctDNA, Cancer, Biomarqueurs, circulating tumoral DNA, Liquid biopsy, Precision medicine, and ddPCR

13 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

The best cancer treatment for all with robust, reliable and data rich proteomics on routinely biobanked FFPE tissue Dedicated to improving cancer care by developing better diagnostic assays for therapy selection. diagnostics, cancer, proteomics, biomarkers, mass spectrometry, tissue, clinical, and quality

30 similar entities Type: Startup Activities: biotech deeptech

Saving lives through innovative molecular diagnostic solutions. Mainz Biomed is aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere. We develop innovative products that quickly and easily identify the early onset of several leading deadly conditions including colorectal and pancreatic cancers. Visit our website www.mainzbiomed.com to learn more about our company and our mission to save lives through science. molecular genetic in-vitro diagnostics

25 similar entities Type: Startup Activities: deeptech biotech

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that are at the forefront of drug discovery and development in oncology and immuno-oncology. Providing a range of integrated solutions, including preclinical research services, translational platforms, and clinical trial support. Its offer includes the world's largest commercially available patient-derived xenograft (PDX) collection and more than 600 tumor organoid models utilizing Hubrecht Organoid Technology, covering 22 cancer indications. Crown Bioscience's expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in …

77 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Early cancer detection in blood AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear. Biotechnology, Cancer Diagnostics, Innovation, Personalized medicine, Blood test, and Biomarkers

81 similar entities Type: Startup Activities: biotech deeptech

Cancer profiling for precision oncology and early cancer detection iCellate develops and provides cancer profiling services for precision oncology. iCellate’s CellMate® is a next generation circulating tumor cell (CTC)-based platform for cancer cell detection and comprehensive biomarker analysis. GeneMate® is an analysis for hereditary cancer and gBRCA testing. Cancer Diagnostics, Circulating Tumor Cells (CTC), Liquid Biopsy, Next Generation Sequencing, CDx, Hereditary Cancer, Early Detection, Cancer, and Solid Tumors

54 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Genomics Imaging for Precision Medicine Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA has grown into a corporate group of companies with world-renowned expertise. The Group offers a unique portfolio that combines NGS services, biomarker …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leader in the development, production and sales of pharmacogenetics tests for cancer precision medicine. Diatech Pharmacogenetics, the leading Italian Precision Medicine company. Diatech Pharmacogenetics is a provider of molecular diagnostic tools for precision medicine. The company aims at simplifying complex molecular diagnostic procedures into easy end-to-end solutions, from nucleic acids extraction and their molecular analysis, to final reporting. The company has 10 years of experience in the successful implementation of several nucleic acid analysis technologies into regulated diagnostic pipelines; examples include pyrosequencing, mass spectrometry and digital molecular barcoding. Leading cancer centres in Italy and abroad rely on Diatech CE-IVD solutions …

34 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Ultra-sensitive and multiplex nucleic acid assays for fast and cost efficient mutation detection in liquid biopsy Rarity Bioscience provides ultra-sensitive multiplex assays for mutation detection in blood and other liquid biopsies for research, pharma and labs. The superRCA technology is based on padlock probes and rolling circle amplification, enabling extreme sensitivity and specificity, and utilize well established high throughput flow cytometry for the read-out. The company was founded in 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology, and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala …

8 similar entities Type: Startup Activities: biotech deeptech